Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Blod and urine concentrations of Procaterol in persons with asthma and elite athletes with asthma: a comparison of inhalation vs. oral administration.

    Summary
    EudraCT number
    		 2010-023346-78
    Trial protocol
    		 DK  
    Global end of trial date
    01 Jan 2016

    Results information
    Results version number
    		 v1(current)
    This version publication date
    09 Feb 2017
    First version publication date
    09 Feb 2017
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    PROCAL2010
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 -
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Bispebjerg University Hospital
    Sponsor organisation address
    Bispebjerg Bakke 23, Copenhagen, Denmark, 2400
    Public contact
    Respiratory Research Unit, Bispebjerg Hospital, mhostrup@nexs.ku.dk
    Scientific contact
    Respiratory Research Unit, Bispebjerg Hospital, mhostrup@nexs.ku.dk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    06 Mar 2016
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    01 Jan 2016
    Global end of trial reached?
    Yes
    Global end of trial date
    01 Jan 2016
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To investigate the pharmacokinetic and pharmakodynamic properties of inhaled vs oral administered procaterol in healthy young men, asthmatics and elite athletes with astma.
    Protection of trial subjects
    Safety of the trial subjects was high prioritized. All procedures are well tolerated and at risk periods, the subjects were under surveillance so that a member of staff could intervene if needed. The study was performed under the GCP-guidelines.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    01 Jun 2011
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Denmark: 20
    Worldwide total number of subjects
    20
    EEA total number of subjects
    20
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    20
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 Recruitment started on the 1st of june 2011 and ended on the 15thof december 2012 Recruitment took place in Denmark, mostly in the Greater Copenhagen Area

    Pre-assignment
    Screening details
    		 # Doctors examination # ECG and pulmonary function testing # Incremental test

    Pre-assignment period milestones
    Number of subjects started
    		 20
    Number of subjects completed
    		 20

    Period 1
    Period 1 title
    Intervention (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Healthy
    Arm description
    		 -
    Arm type
    		 Experimental

    Investigational medicinal product name
    Procaterol
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder and solvent for nebuliser solution, Tablet
    Routes of administration
    Oral use, Not mentioned
    Dosage and administration details
    4 µg procaterol was administered as nebulization 100 µg procaterol was administered orally.

    Arm title
    		 Asthmatic
    Arm description
    		 -
    Arm type
    		 Experimental

    Investigational medicinal product name
    Procaterol
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder and solvent for nebuliser solution, Tablet
    Routes of administration
    Not mentioned , Oral use
    Dosage and administration details
    4 µg procaterol was administered as nebulization 100 µg procaterol was administered orally.

    Number of subjects in period 1
    		Healthy Asthmatic
    Started
    10
    10
    Completed
    10
    10

    Baseline characteristics

    		 Close Top of page

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Healthy
    Reporting group description
    		 -

    Reporting group title
    Asthmatic
    Reporting group description
    		 -

    Primary: Urine concentrations

    		 Close Top of page
    End point title
    		 Urine concentrations
    End point description
    End point type
    Primary
    End point timeframe
    During whole trial
    End point values
    		 Healthy Asthmatic
    Number of subjects analysed
    10
    10
    Units: ng/ml
        median (standard error)
    47 ± 12
    28 ± 9
    Statistical analysis title
    		 Repeated-measures analysis
    Comparison groups
    Healthy v Asthmatic
    Number of subjects included in analysis
    20
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 ≤ 0.05
    Method
    		 ANOVA
    Parameter type
    		 Mean difference (final values)
    Confidence interval
         level
    		 95%
         sides
    1-sided
         lower limit
    		 -
         upper limit
    		 -
    Variability estimate
    Standard deviation

    Adverse events

    		 Close Top of page
    Adverse events information [1]
    Timeframe for reporting adverse events
    From inclusion until 1 week post end of trial
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 National Authority
    Dictionary version
    1
    Reporting groups
    Reporting group title
    Procaterol
    Reporting group description
    		 -

    Serious adverse events
    		 Procaterol
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 20 (0.00%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    Frequency threshold for reporting non-serious adverse events: 1%
    Non-serious adverse events
    		 Procaterol
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    0 / 20 (0.00%)
    Notes
    [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
    Justification: No adverse events have been reported.

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported

    Online references
    http://www.ncbi.nlm.nih.gov/pubmed/26990656
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 05 11:05:03 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA